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Summary.-The results of using a standard combination of cytotoxic agents in
27 cases of secondary liver cancer are reported. A brief review of the methods
available for treating hepatic metastases from solid tumours, as opposed to lympho-
mata, is included. The response rate depends on the site of the primary lesion.
It is suggested that in patients with mammary or colorectal primary tumours,
combination chemotherapy represents an advance in treatment with an objective
response rate of 730/% and 66% respectively in the 2 groups. The method requires
no specialized equipment as neither grossly deranged liver enzymes nor jaundice
are contra-indications to treatment, and toxicity is easily monitored and readily
controlled.
CHEMOTHERAPEUTIC REGIMEN
In 1971 Hanham, Newton and West-
bury reported on 75 cases treated with
quadruple chemotherapy using a modifica-
tion of the regimen devised by Costanzi
and Coltman (1969). We have continued
to use this regimen and this report
concerns those patients in the first 150
treated by quadruple chemotherapy who
had hepatic metastases.
Liver biopsy is not performed as a
routine on patients suspected of having
metastases, thus antemortem histological
confirmation of liver involvement was
not always available. Hepatic metastases
were therefore diagnosed when 3 or more
of the following were present: (1) Hepato-
megaly; (2) raised alkaline phosphatase
level; (3) raisedaspartate aminotransferase
(SGOT) level; (4) evidence of hepatic
metastases on gamma scan.
Of the 150 patients reviewed, 27 had
hepatic metastases on these criteria.
This figure is lower than might be expected
and this is largely explained by the high
proportion of head and neck cancers.
Of these 27 patients, 11 had primaries
in the breast, 9 had colorectal primaries
and 7 had primaries in other sites (2
bronchus, 2 ovary, 2 melanoma and
1 stomach).
All patients were given quadruple
chemotherapy in a 5-day course, with
3 weeks' lapse between courses. The
drugs and their dosage are given in
Table I. In patients who were jaundiced
TABLE I
Cyclophosphamicle
Methotrexate
Vincristine
5-Fluorouracil
300 mg 2 doses Days 1 and 5.
0 5 mg/kg body weight/day
2 doses Days 1 and 4.
0-025 mg/kgbodyweight/day 2
doses Days 2 and 5.
10 mg/kg body weight/day-
daily.
or had a white cell count below 4000/mm3
halfthe dose shown was given.
In order to be considered as showing
an objective response to treatment, a
patient had to complete a minimum of
3 courses of chemotherapy and to show
improvement in 3 or more of the above
parameters. A subjective improvement
was judged by an increase in the patient's
performance as assessed by the Karnofsky
scale (Karnofsky and Burchenal, 1948).
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clinical assessment and 1
were performed. Gam
liver were taken in most
mately 2-monthly intern
RESULT
Other reports have
prognosis in patients
deposits in the liver de
of the primary lesion
1969; Jaffe et al., 19(
showed this quite clear]
cided to divide the patie
breast primary (11 (
primary (9 cases) and ot
The overall results for t
summarized in Table I:
TABLE ]
Site of primary tumour
Number of patients with
hepatic secondaries
Objective response to
chemotherapy
Subjective response only
Liver function tests in 8 of 11 cases (730%); a subjective re-
ma scans of the sponse was seen in 2 of the remaining
t cases at approxi- cases. The mean survival for this group
vals. was 13 months (from the time when
hepatic secondaries were first diagnosed).
s Four patients are still alive and well at
shown that the 20, 16, 15 and 14 months respectively.
with secondary One patient died from causes not directly
pend . thesiterelated to her malignant disease. In 6
(Mansfield et als cases, initially abnormal liver enzyme
68)( Our results values (alkaline phosphatase and SGOT) 38). Our resus de returned to within normal limits. In lyands into3wasude several cases gamma scans showed actual bnts into 3 groups:
cases), colorectal regeneration of functioning liver tissue
,her sites (7 cases). (Fig. 1).
ihese 3 groups are In patients with colorectal primaries, 1.ese 3 groIIIs are an objective response was noted in 6 out
of 9 (66%), asubjective response was seen
in one of the remaining cases. The mean
[I survival time was 9 months and 2 patients
Colo- are alive and well at 12 and 22 months
reast rectal Other respectively. Although the level of ab-
11 9 7 normality ofliver enzymes was reduced in
several cases, in no instance did these
8 6 0 levels return to normal with chemo-
2 1 2 therapy. Again, some scans showed
II ~~~~regeneration of liver tissue (Fig. 2).
In the group of patients with miscel-
3 (total no. II): laneous primary sites, the response was
Improved poor. No objective responses were noted
Present with and only 2 patients showed subjective initially treatment improvement, one with a bronchial pri-
10 8 mary, the other with carcinoma of the
10 8 stomach. Only one patient in this group 9 8 is still alive after 12 months.
B
TABLE II
Patients with breast primaries
Hepatomegaly
Raised alkaline phosphatase
Raised SGOT
Abnormal liver scan
Patients with colorectal prima]
Hepatomegaly
Raised alkaline phosphatase
Raised SGOT
Abnormal liver scan
ries (total no. 9):
Improved
Present with
initially treatment
7
9
8
8
4
6
5
4
more detailed analysis showing the num-
ber ofpatients in the breast and colorectal
groups who had hepatomegaly, abnormal
liver enzymes and abnormal gamma scans,
and which ofthese respondedtotreatment.
In patients with breast primaries, an
objective response to treatment was seen
DISCUSSION
A variety of methods have been
employed in the management ofsecondary
hepatic cancer including surgical, radio-
therapeutic and chemotherapeutic tech-
niques.
In America, Dillard (1969) and
Flanagan and Foster (1967) have reported
favourably on resection of hepatic meta-
stases. The indications are limited, how-
ever, and Smith (1964), reviewing his own
figures in this country, stressed that " the
most favourable case is the single large
metastasis several years after resection
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(a)
(b)
FIG. 1.-Gamma scans of a patient with hepatic metastases from a primary breast tumour, (a) immediately
before combination chemotherapy, (b) 15 months later, still on chemotherapy.
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(a)
(b)
Fia. 2.-Gamma scans ofa patient with hepatic metastases from a primary colonic tumour, (a) immediately
before combination chemotherapy, (b) 20 months later, still on chemotherapy.
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of the primary ". Hepatic artery ligation
wasfoundtogivereliefofpain andto induce
remissions of up to 10 months in the series
reported by Murray-Lyon et al. (1970),
although some of their patients were
treated by portal vein perfusion with
cytotoxic agents as well. Adrenalectomy
for patients with hepatic secondaries from
breast primaries seems to have little to
offer, Fracchia, Randall and Farrow
(1970) reporting only a 13% response rate.
However, Wilson et al. (1971) combined
adrenalectomy and systemic 5-fluorouracil
therapy and obtained a 3900 response rate.
Ingold et al. (1965) demonstrated the
relatively low radiation tolerance of the
liver to a dosage of 3000 rads given in
3 weeks, and this limits the use ofexternal
radiotherapy to the relief of pain in a few
patients with advanced hepatic disease.
Ariel, in 1960, first reported using radio-
active isotopes in the treatment of
hepatic secondaries. The isotopes were
injected percutaneously into metastases
whose location had been determined by
gamma scanning. Later (Ariel, 1965) he
used yttrium 90 attached to microspheres
of ceramic 100-200 /um in diameter which
were injected intra-arterially. Both these
techniques gave useful palliation. More
recently, Ariel and Pack (1967) have
compared the results of microsphere
irradiation with chemotherapy for hepatic
secondaries in a group of patients, the
majority of whom had colorectal pri-
maries; 27% ofcases achieved an objective
response with chemotherapy, 320% with
microsphere isotopes and 4700 when the
2 techniques were combined.
Following a prospective trial on
patients with hepatic metastases from
colorectal primary tumours, Rapoport and
Burleson (1970) concluded that systemic
5-fluorouracil neither prolonged survival
nor offered a high chance of response.
Lahiri, Boileau and Hall (1971), using
oral 5-fluorouracil, showed good remission
in a small series but only patients expected
to survive a minimum of 3 months were
considered for treatment.
Most chemotherapeutic regimens for
hepatic secondaries have been by infusion
techniques. The surgical aspects have
been reviewed by Labelle et al. (1968)
and XVatkins, Khazei and Nahra (1970).
Ariel and Pack (1965) concluded that
there was no difference in response rates
when catheters were located in the hepatic
artery or the aorta, that methotrexate and
5-fluorouracil were equally effective, and
that no superiority of an intermittent
technique over continuous infusion could
be demonstrated. In terms of patient
response and survival the reports differ.
Sullivan, Norcross and Watkins (1964),
Sullivan and Zurek (1965), Ariel and Pack
(1965), Brennan et al. (1963) and Burrows
et al. (1967) all give optimistic results, in
series with response rates of up to 6000,
in patients with colorectal primaries.
However, Lawrence (1965) concludes that
the benefit is so small that it does not
justify the discomfort and possible compli-
cations of the procedure.
The prognosis for patients with hepatic
metastases is poor. Jaffe et al. (I1968)
gave a median survival time of 75 days in
their series, but they stressed that the
site of the primary tumour influenced the
prognosis and the median survival time
for patients with colorectal primaries
was 146 days. They concluded that to
show an advance, treatment must increase
the survival time of 5000 of patients with
colorectal primary tumours to over 5
months. In a smaller series, Donegan,
Harris and Spratt (1969) gave a median
survival time of 4t months in untreated
cases.
Our results in patients with primary
breast tumours show an advance on all
previous methods of treatment, with a
mean survival of 13 months and 4000 of
the patients still alive. Two cases are
of particular interest in that their hepatic
involvement presented with jaundice.
This would normally be considered a
contra-indication to most of the methods
oftreatment reviewed. It was considered,
however, that a trial of chemotherapy was
justified and at the time of commencing
treatment their total serum bilirubin
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levels were 23 mg/100 ml and 13.8 mg/
100 ml respectively. In both patients
the serum bilirubin level was within
normal limits after 2 courses of chemo-
therapy.
The results in the group with colorectal
primaries are less dramatic although they
do compare favourably with most of the
treatments reviewed. It must be remem-
bered, however, that we exercised no form
ofpatient selection. Anyone with hepatic
metastases, regardless of advanced dis-
ease, metastases elsewhere, grossly de-
ranged liver function tests or jaundice,
was treated. Furthermore, the treatment
required no special surgical skills nor any
specialized equipment.
Our results in patients whose primaries
come from other sites must be considered
inconclusive; the numbers involved were
too small to draw any definite conclusions.
All that can be said is that combination
chemotherapy is probably worth trying
in the otherwise untreatable case.
There was no objective evidence of
hepatotoxicity from the treatment. The
toxic effects seenwereleucopenia, alopecia,
nausea and vomiting. The patients had
regular blood counts during treatment and
the dosage was adjusted if leucopenia
developed. The incidence of alopecia was
reduced by using a scalp tourniquet.
Nausea and vomiting were treated with
routine antiemetics. In no case did
toxicity necessitate stopping treatment.
We would like to thank the surgeons
and fellow radiotherapists who referred
patients for quadruple chemotherapy.
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